Micardis, Pritor(telmisartan)
Kinzalkomb, Kinzalmono, Micardis, Pritor, PritorPlus, Twynsta (telmisartan) is a small molecule pharmaceutical. Telmisartan was first approved as Micardis on 1998-11-10. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. It has been approved in Europe to treat essential hypertension and hypertension. The pharmaceutical is active against type-1 angiotensin II receptor. In addition, it is known to target peroxisome proliferator-activated receptor gamma.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
cardiovascular diseases | D002318 |
endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Micardis (generic drugs available since 2014-01-08)
CombinationsMicardis (generic drugs available since 2014-01-08, discontinued: Twynsta)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amlodipine besylate
+
Telmisartan
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TWYNSTA | Boehringer Ingelheim | N-022401 DISCN | 2009-10-16 | 4 products, RLD |
Hide discontinued
Hydrochlorothiazide
+
Telmisartan
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MICARDIS HCT | Boehringer Ingelheim | N-021162 RX | 2000-11-17 | 3 products, RLD |
Telmisartan
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MICARDIS | Boehringer Ingelheim | N-020850 RX | 1998-11-10 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
micardis hct | New Drug Application | 2022-12-19 |
telmisartan | ANDA | 2023-06-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
diabetic nephropathies | EFO_0000401 | D003928 | — |
heart failure | EFO_0003144 | D006333 | I50 |
hypertension | EFO_0000537 | D006973 | I10 |
left ventricular dysfunction | — | D018487 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09CA07: Telmisartan
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DA07: Telmisartan and diuretics
— C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
— C09DB04: Telmisartan and amlodipine
HCPCS
No data
Clinical
Clinical Trials
276 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 14 | 6 | 54 | 39 | 46 | 159 |
Healthy volunteers/patients | — | 39 | — | — | 1 | — | 40 | ||
Dyslipidemias | D050171 | HP_0003119 | 4 | — | 3 | 1 | 1 | 9 | |
Covid-19 | D000086382 | U07.1 | — | 5 | 4 | 1 | — | 8 | |
Essential hypertension | D000075222 | I10 | 3 | 1 | 1 | 3 | — | 8 | |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 3 | 4 | 1 | 8 |
Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | 4 | 1 | 6 | |
Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | 3 | 3 | — | 6 |
Coronary artery disease | D003324 | I25.1 | — | 1 | 1 | 3 | — | 4 | |
Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | 1 | 1 | 1 | 3 |
Show 16 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | 7 | — | 3 | — | — | 10 |
Hypercholesterolemia | D006937 | HP_0003124 | — | — | 3 | — | — | 3 | |
Cerebral hemorrhage | D002543 | — | — | 2 | — | 1 | 3 | ||
Sars-cov-2 | D000086402 | — | 2 | 2 | — | — | 2 | ||
Cerebral small vessel diseases | D059345 | — | — | 1 | — | 1 | 2 | ||
Vascular dementia | D015140 | F01 | — | — | 1 | — | 1 | 2 | |
Hypertriglyceridemia | D015228 | EFO_0004211 | 1 | — | 1 | — | — | 2 | |
Polycystic kidney diseases | D007690 | Q61.3 | — | — | 2 | — | — | 2 | |
Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | 1 | 1 | — | — | 1 | |
Hemorrhagic stroke | D000083302 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | — | — | — | 3 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 2 | — | — | — | 2 |
Insulin resistance | D007333 | EFO_0002614 | — | 1 | — | — | 1 | 2 | |
Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | — | 1 |
Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 1 | — | — | — | 1 |
Neuralgia | D009437 | EFO_0009430 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 1 | — | — | — | — | 1 |
Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 | ||
Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 1 | 1 |
Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | 1 | 1 | |
Neoplasms | D009369 | C80 | — | — | — | — | 1 | 1 | |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 1 | 1 |
Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | — | — | 1 | 1 |
Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TELMISARTAN |
INN | telmisartan |
Description | Telmisartan is a member of the class of benzimidazoles used widely in the treatment of hypertension. It has a role as an antihypertensive agent, an angiotensin receptor antagonist, an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, a xenobiotic and an environmental contaminant. It is a member of biphenyls, a member of benzimidazoles and a carboxybiphenyl. |
Classification | Small molecule |
Drug class | angiotensin II receptor antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1 |
Identifiers
PDB | 3VN2 |
CAS-ID | 144701-48-4 |
RxCUI | 73494 |
ChEMBL ID | CHEMBL1017 |
ChEBI ID | 9434 |
PubChem CID | 65999 |
DrugBank | DB00966 |
UNII ID | U5SYW473RQ (ChemIDplus, GSRS) |
Target
Agency Approved
AGTR1
AGTR1
Organism
Homo sapiens
Gene name
AGTR1
Gene synonyms
AGTR1A, AGTR1B, AT2R1, AT2R1B
NCBI Gene ID
Protein name
type-1 angiotensin II receptor
Protein synonyms
Angiotensin II type-1 receptor, AT1 receptor, AT1AR, AT1BR, type-1B angiotensin II receptor
Uniprot ID
Mouse ortholog
Agtr1b (11608)
type-1 angiotensin II receptor B (P29755)
Alternate
PPARG
PPARG
Organism
Homo sapiens
Gene name
PPARG
Gene synonyms
NR1C3
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor gamma
Protein synonyms
Nuclear receptor subfamily 1 group C member 3, peroxisome proliferator-activated receptor-gamma 5, peroxisome proliferator-activated receptor-gamma splicing, PPAR-gamma
Uniprot ID
Mouse ortholog
Pparg (19016)
peroxisome proliferator-activated receptor gamma (P37238)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,679 documents
View more details
Safety
Black-box Warning
Black-box warning for: Micardis hct, Telmisartan
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
425 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more